He still loses his mind when the lead comes off the hook. He just takes the stairs one at a time now.
The walk that used to be an hour is comfortably forty minutes.
He gets up more slowly than he did last winter, and you noticed the exact week it changed.
That slope has a biology behind it. For the first time, that biology is something a veterinarian can act on rather than describe.
Routine care is built to treat disease once it arrives — the lump, the limp, the lab value that finally crosses a line. It is not built to slow the process that produces them.
You are the kind of owner who reads the bloodwork rather than filing it. Who knows what his breed dies of, and roughly when.
That is the right instinct. Aging is now a research target in its own right, and dogs are where the most serious work is happening.
healthy lifespan across mammalian studies — the most reproducible result in aging research.
Rapamycin extended median lifespan in mice even when treatment began in late middle age, replicated across strains and both sexes. No other compound has matched that record. Whether it holds in dogs is the question the NIH-funded Dog Aging Project is now testing in TRIAD — the largest clinical trial in veterinary history, which has not yet reported.
The years matter less than what is in them. Healthspan is whether he still behaves like the dog you remember.
Rapamycin acts on mTOR — the pathway that decides whether cells grow or repair themselves. Each card leads with what has been established, and says plainly where the line is.
Rapamycin extends healthy lifespan by up to 14% across mammalian studies, and does it even when started in late middle age — replicated across strains and both sexes. Nothing else in aging research has that record. In dogs the same question is being asked at scale by the NIH-funded TRIAD trial, which has not yet reported.
In a placebo-controlled pilot in middle-aged dogs, ten weeks of low-dose rapamycin improved echocardiographic measures of cardiac function, with no significant adverse effects at the doses used. That result is what motivated the larger canine effort. It is a small, short trial — improved function, not a reversed disease.
mTOR inhibition is an established anticancer mechanism in human oncology, and the pathway is implicated in several of the cancers that take dogs most often. That is why it is being studied. No canine trial has shown that rapamycin reduces cancer incidence, and any page telling you otherwise is ahead of the evidence.
Chronic low-grade inflammation drives much of the stiffness owners notice first, and partial mTOR inhibition lowers that signalling — while at these low weekly doses several studies report improved immune response rather than suppression. Owners frequently report easier movement; that is their experience, not a measured outcome.
Thirteen years old, a Labrador, and slowing in the way Labradors do: the back end first, then the enthusiasm. His owner had already had the conversation with herself about how much time was left.
A check with his own vet turned up no exclusions — no diabetes, clean liver values, no surgery planned. He started on a weight-calibrated protocol, once weekly, with bloodwork at six weeks and again at four months.
By late summer he was running on the beach. He is fourteen now. He still takes the stairs carefully, and he still gets there.
One dog’s course is not a result you should expect. Individual outcomes vary, and this story is not a medical claim.
Most dogs that start are healthy. In large and giant breeds, “middle-aged” arrives earlier than owners expect.
It is not right for every dog. Diabetes or impaired glucose regulation, active infection, significant liver or kidney disease, planned surgery, or pregnancy all rule it out — so check each of these with your own veterinarian before starting.
The molecule is the easy part. Dose, schedule, screening and monitoring are what make it work — and what make it safe.
A 12 kg spaniel and a 60 kg mastiff are not on the same milligram dose. Longevity dosing is a fraction of transplant dosing, and intermittent rather than daily. Confirm the exact dose with your own vet before starting.
One capsule on a fixed weekly rhythm — the schedule the current TRIAD longevity protocol uses. Consistency matters more than precision timing; it is built to be sustainable.
History, current medications and baseline bloodwork, all with your own vet. Rapamycin is metabolised through CYP3A4, so interactions are checked rather than assumed.
Bloodwork at intervals, weight tracked throughout, and the dose adjusted by your own vet as his body and his health change. Dosing pauses around planned surgery, because mTOR inhibition can slow wound healing.
Given properly, this is a monitored medical protocol. Given without oversight — wrong dose, no screening, no bloodwork, unchecked interactions — it is neither safe nor useful. That is why your own vet belongs in it from the first dose.
Rapamycin is a prescription medicine. Use it only under the guidance of your own veterinarian.
Already have a vet who knows your dog? Bring them the protocol. We will share the published research behind the dose and the monitoring, so your vet can make the call.
Read the science →The strength for your dog’s body weight, one box at a time — order again when you need more. Check the strength with your own vet first.
See the dog medicine →What is another two good years with him worth? We can’t price that. We can tell you what the programme costs, and exactly what is in it.
Longevity medicine is not about getting hold of a molecule. It is about the right dose, the right monitoring, at the right time — and knowing when the answer is no. That judgment belongs to a veterinarian who has examined your dog, so bring your own vet in before the first dose. The medicine is the easy part; the care around it should adapt as your dog ages.
Start by taking the protocol to your own vet. If your dog is not a candidate, that answer is worth knowing too.
This page is educational and is not veterinary advice. Rapamycin is a prescription medicine; whether to use it is a decision made with a veterinarian who has examined your animal. No medicine is licensed to “extend longevity” — the statements here describe published research and ongoing studies.